Diabetes

While diabetes is a growing national health threat, it's especially prevalent in Mississippi, where 1 in 8 residents are diabetic.

Fixed-ratio combination of basal insulin glargine 1and GLP-1 receptor agonist lixisenatide shpws promise in adults with type 2 diabetes.

Susan Cornell, PharmD, CDE, FAPhA, FAADE forecasts the future landscape for antidiabetic agents recommended as a second-line treatment for type 2 diabetics.

Susan Cornell, PharmD, CDE, FAPhA, FAADE discusses the patient counseling points pharmacists should be aware of for antidiabetic agents.

Susan Cornell, PharmD, CDE, FAPhA, FAADE outlines the classes of antidiabetic agents recommended as a second-line treatment for type 2 diabetics.

Verapamil shows promise for patients with type 1 diabetes or type 2 diabetes and damaged beta cells.

Drugs like Viagra could improve insulin sensitivity and secretion without diminishing fibrinolytic function.

Diabetes drug liraglutide may cause insulin-producing beta cells to deteriorate.

Erectile dysfunction drugs may improve insulin sensitivity and secretion in patients with prediabetes.

The FDA has accepted for review Sanofi's new drug application for its fixed-ratio combination of basal insulin glargine 100 units/mL and lixisenatide for the treatment of type 2 diabetes.

Diabetes and other conditions are also influenced by a person’s height.

Diabetes is a complex autoimmune condition that requires many treatment and education strategies to achieve health goals beyond glycemic control.

Type 1 diabetes is an autoimmune disease in which the beta cells of the pancreas are destroyed and are unable to produce an adequate amount of the hormone insulin.

The FDA has approved Tresiba (insulin degludec injection) to improve glycemic control in adults with diabetes mellitus.

Encapsulated human islet cells could improve maintenance of blood sugar levels in patients with diabetes.

Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.

Diabetes is not a fun condition.

Medication adherence outreach should target patients who have multiple out-of-network claims.

Predictors of poor medication adherence include increased regimen complexity, multiple comorbidities, and high medication cost.

Supplementing insulin therapy combined with other glucose lowering agents may improve outcomes for T1DM patient.

Supplementing insulin therapy combined with other glucose lowering agents may improve outcomes for T1DM patient.

More than 20,000 articles have been written on how poor medication adherence, which costs the United States between $68 to $146 billion annually, increases adverse clinical outcomes and mortality.

Once-daily, long-acting basal insulin was approved in September 2015 for improving glycemic control in adults with diabetes.

Once-daily, long-acting basal insulin was approved in September 2015 for improving glycemic control in adults with diabetes.

Novo Nordisk's insulin degludec injection is now available in pharmacies nationwide.